INTRODUCTION
The combination of the antifolate drugs sulfadoxine and pyrimethamine (SP) has served as the first line of defense against chloroquine-resistant Plasmodium falciparum malaria and remains an available and affordable alternative for the treatment of uncomplicated malaria in many areas of the world. On the Pacific coast of Colombia, chloroquine resistance is present at the high levels characteristic of much of South America, but SP resistance has remained low.1 Resistance to SP usually arises in areas where its use is extensive2 and strategies to deter the emergence and spread of resistance to SP and other antimalarial drugs are needed.
We previously reported that parasite mutations that confer low-level resistance to SP may contribute to the potential for transmission of Plasmodium falciparum and the spread of resistance.1 In a setting with an SP treatment failure rate less than 4%, point mutations in parasite dihydrofolate reductase (DHFR) that confer in vitro resistance to pyrimethamine were associated with longer parasite clearance time (PCT) and the presence of gametocytes (the sexual form of the parasite responsible for transmission by the mosquito vector) after SP treatment. This suggested that even before clinical SP resistance is apparent, drug treatment that eradicates the asexual parasites that cause disease may still lead to the spread of resistance by selecting for resistant parasites that survive and propagate in the form of gametocytes.
More than 50 years ago, in vitro studies showed that strains of P. gallinaceum that became resistant to antifolates by growth under drug pressure exhibited a higher count of gametocytes.3 More recently, chloroquine treatment of P. falciparum has also been shown not only to lead to an increase in gametocyte numbers, but also to increased numbers of oocysts in mosquitoes fed on patients infected with chloroquine-resistant parasites.4,5 The transmission potential of SP-resistant parasites is unknown. Our recent data highlight the importance of investigating the role of low-level drug resistance mutations on the selection and the spread of drug resistance in its earliest stages.
In this study, we assessed the association between the occurrence of mutations in P. falciparum DHFR and dihydropteroate synthase (DHPS) and transmission capacity of parasites to Anopheles mosquitoes. In particular, we compared the prevalence of DHFR and DHPS point mutations before (in asexual parasites) and after (in gametocytes) SP treatment and determined parasite infectivity to Anopheles mosquitoes of post-treatment gametocytes with and without DHFR and DHPS mutations.
MATERIALS AND METHODS
Study area.
The study was carried out in Buenaventura, Colombia, a seaport located in a highly humid tropical forest zone on the Pacific coast of Colombia, with a mean temperature of 28°C and annual rainfall ranging from 6,000 to 9,000 mm.6 The municipality has approximately 300,000 inhabitants, 85% of whom live in the urban area. Malaria is hypoendemic and its incidence has a long-term periodicity with peaks occurring every four years. A total of 50–80% of the malaria is caused by P. falciparum. The annual incidence is 60–100/1,000 in the rural area and 1–3/1,000 in the urban area. Malaria occurs throughout the year, with two seasonal peaks usually between April and May and between September and October.7 In the port of Buenaventura, malaria is clustered in the periurban zone, which accounts for almost 70% of urban cases and where all breeding sites for Anopheles spp. are located,8 primarily An. albimanus, the main vector of malaria on the Pacific coast of Colombia.9
Study population.
Subjects were recruited from outpatient clinics and at a field research station in Buenaventura. Malaria patients who fulfilled entry criteria were invited to participate in the study. Inclusion criteria were an age more than 5 years, a positive blood smear for P. falciparum malaria, informed consent from participant or parent, and intention to remain in the study area for at least four weeks from the time of enrollment. Patients with mixed species infections and those with clinical symptoms or laboratory results confirming or suggesting complicated malaria were excluded.
Ethical issues.
The protocol and the informed consent document were reviewed and approved by the Universidad del Valle Ethical Review Board in Cali, Colombia, before commencement of the study. The informed consent document was read to the subject, parent, or guardian of prospective participants and a copy was given to the subject.
Treatment and assessment of parasite and clinical responses.
Individuals received a single oral dose of SP equivalent to 1.25 mg/kg of pyrimethamine 25 mg/kg of sulfadoxine up to a maximum dose of 75 mg of pyrimethamine and 1,500 mg of sulfadoxine. To monitor for adverse reactions and to make sure the medicine was well tolerated, all subjects were observed for at least 60 minutes. If vomiting occurred within 30 minutes, the full dose was repeated, and if vomiting occurred between 30 and 60 minutes, half of the dose was repeated. All patients also received an insecticide-impregnated bed net to decrease the likelihood of reinfection.
On enrollment and prior to treatment, symptoms and findings of a physical examination were recorded. We used a slightly modified version of the 2003 World Health Organization (WHO) protocol for measuring antimalarial drug efficacy in areas with low transmission.10 Follow-up was by active surveillance visits on days 1, 2, 3, 7, 14, 21, and 28, with an additional evaluation on day 4 if the blood smear remained positive on day 3. Every visit included physical examination, determination of blood hemoglobin concentration, and blood smear for malaria diagnosis.
Thick smears were stained with Field’s stain and read immediately for initial parasitemia screening. An experienced laboratory technician measured asexual parasitemia (asexual parasites/microliter of blood) by reading 200 high-power fields on a second Giemsa-stained thick blood film. Thin smears were preserved for Giemsa staining and parasite identification. We defined PCT as the number of days to the first negative parasitemia after treatment.
Polymerase chain reaction (PCR) detection of DHFR and DHPS mutations.
At days 0, 7, 14, 21 and 28 after treatment, finger stick blood from infected individuals was blotted onto strips of filter paper, air-dried, and stored at room temperature in separate plastic envelopes for PCR analysis of DHFR and DHPS mutations. Parasite DNA was extracted using a simple methanol fixation heat extraction method that relied on chelating resin extraction only for occasional samples that did not amplify well after methanol extraction. The PCR methods to assess parasite mutations were applied according to protocols described elsewhere11 (available from http://medschool.umaryland.edu/CVD/plowe.html).
Our analyses were limited to mutations that have been shown to be of primary prevalence in the area: DHFR mutations at codons 108 (serine to asparagine) and 51 (asparagine to isoleucine) and DHPS mutation at codon 437 (ala-nine to glycine). Evaluation of other mutations was initiated and discontinued if a mutation was not found in the first 50 samples tested during follow-up: DHFR-59 (cysteine to argi-nine), DHFR-164 (isoleucine to leucine) DHPS-581 (alanine to glycine) and DHPS-540 (lysine to glutamate). For all assays, infections were determined to be wild-type, mutant, or mixed with respect to each mutation site, based on agarose gel electrophoresis of diagnostic PCR or restriction digestion products. Samples found mutant at DHFR-51 that were not amplified for DHFR-108 were considered double mutant because this last point mutation always precedes subsequent mutations. In addition, samples found with no mutant at DHFR-51 and not amplified for DHFR-108 were grouped as wild or DHFR-108 only mutant.
Gametocytemia (transmission potential).
From samples taken to evaluate parasite response from days 0 to 28, we also measured sexual stage (gametocyte) production. Using the same technique described above to count asexual forms, we quantified the number of gametocytes/microliter.
Parasite infectivity to Anopheles mosquitoes.
Blood samples were collected by venipuncture of patients on days 0, 7, 14, 21, and 28 after treatment. Five milliliters of whole blood were collected in tubes containing EDTA as anticoagulant. Blood cells were separated from plasma by centrifugation at 3,000 rpm for 5 minutes and plasma was replaced by a similar volume of normal human plasma known to sustain malaria transmission. This step was performed to avoid the possible interference (blocking or enhancing) antibodies to gametocytes in the donor’s plasma. Laboratory-reared An. albimanus mosquitoes of the Buenaventura strain were used for the evaluation of transmission capacity by using membrane feeding assays (MFAs) at the field site laboratory as described elsewhere.12 Briefly, batches of 200–300 mosquitoes per cage were used 2–3 days after emergence. All experiments were conducted at room temperature (approximately 25°C) within one hour after patient bleeding. A total of 2–3 mL of the test blood was injected into glass feeders maintained at 40°C and mosquitoes were allowed to feed for approximately 15 minutes. After feeding was completed, mosquitoes were maintained at standard rearing conditions (temperature = 27°C and relative humidity = 80%). Seven to eight days after feeding, surviving mosquitoes were dissected and analyzed to determine the presence of oocysts in the midgut. The proportion of infected mosquitoes and the oocysts count were determined for each mosquito batch.
Statistical analysis.
In evaluation of the selection of the mutant parasites, the exposure of interest was the status of mutations in asexual parasite genes before therapy and the endpoint of interest was the status of the mutations in the sexual forms after treatment. We used the McNemar test for this paired analysis. To control for potential confounders (e.g., level of parasitemia), we used conditional logistic regression whereby each participant contributed two records for the analysis: one before treatment (i.e., unexposed) and one after treatment (i.e., exposed).
We also performed an analysis based on marginal probabilities by determining whether the 95% confidence interval (CI) for the overall probability of having two mutations after treatment (p) included the probability of having two mutations before treatment (q). It was expected that if the lower bound of the 95% CI of p was greater than q, we could conclude that there was proliferation of mutations linked to increasing resistance.
We determined infectivity before and after SP treatment. The proportion of infected mosquitoes and the mean number of oocysts among infected mosquitoes were calculated. We determined the significance of the infectivity by using exact methods to calculate the 95% CI of the average proportion of infectious mosquitoes. To test for the potential heterogeneity of this proportion according to the type of mutations in the sexual form, we developed an empirical logistic regression with the observed log odds of infected mosquitoes as the outcome. We allowed proportions equal to zero to be included in this analysis by replacing with a constant (i.e., 0.5) all MFA results with zero infected mosquitoes. In addition, we carried out simple linear regression methods to similarly test for heterogeneity in the mean number of oocysts counts among infected mosquitoes.
RESULTS
A total of 166 patients with acute P. falciparum malaria were enrolled in the study between March 2004 and December 2005 and all received standard SP treatment. One individual was lost to follow-up on day 2 without parasite clearance having been observed and was excluded from the analysis. Ten individuals cleared parasitemia, but were followed for less than seven days and also were excluded. The remaining 155 comprised the study population for the analysis. Subjects were between 6 and 72 years of age (median = 26.7 years) and 96 (61.9%) of 155 were males. Parasitemias at enrollment ranged between 80 and 83,440 parasites/μL with a geometric mean of 5,300 parasites/μL.
Table 1 summarizes treatment responses and follow-up periods among all study participants. According to the standard criteria (WHO test) for parasitologic and clinical evolution after SP therapy, seven patients developed an early treatment failure (i.e., during the first three days after treatment). All received rescue treatment with quinine and were followed-up until complete recovery. Adequate clinical and parasitologic response was observed in 16 patients with follow-up periods of 7–21 days (16 of 155, 10.3%) and in 132 patients with complete follow-up until day 28. The per-protocol treatment efficacy (including only patients with complete follow-up) was 95.0% (132 of 139).
Point mutations at DHFR and DHPS codons before and after therapy.
The DHFR and DHPS mutations at enrollment and during follow-up visits are summarized in Table 2. Mutations at DHFR codons 59 and 164 and at DHPS codons 581 and 540 were not found in this study after processing all samples at enrollment. During follow-up, after processing at least half of the available samples, these mutations were also found to be absent and assays for them were discontinued.
All samples with the DHFR 51 mutation also carried the serine to asparagine mutation at DHFR codon 108. Therefore, infections in individuals were categorized by their DHFR mutations as no mutation, 108 mutant only, or 108 and 51 mutants (Table 3). Marginal probability of finding any DHFR mutation (108 mutant only or 108 and 51 mutants) increased from 86.3% (95% CI = 79.8–91.3) on day 0 to 93.6% (95% CI = 82.5–98.7) and 100% (95% CI = 90.3–100) on days 21 and 28, respectively. Double-mutant parasites were less frequently observed at enrollment (i.e., 58.8% among asexual parasites) than on day 7 (i.e., 70.8% among gametocytes), but this difference was not significant (P = 0.17).
Paired analysis for presence of double-mutant parasites before and after therapy showed significant selection of mutant parasites (Table 4). Of the 19 individuals with discordant mutation status in days 0 and 7, 15 individuals whose infections on day 0 were not mutant or 108 single-mutant had double-mutant infections by day 7 (P = 0.019). The magnitude of the association (odds ratio [OR] = 3.8, 95% CI = 1.2–15.5) confirmed a substantial force of selection of mutant parasites seven days after SP treatment. This association remained significant and was even stronger after adjusting by the level of parasitemia (OR = 4.9, 95% CI = 1.2–20.0). The corresponding estimates (i.e., OR) for matched comparisons of mutant occurrence between days 0 and 14 and between days 0 and 28 were 2.3 (95% CI = 0.8–7.4) and 7.0 (95% CI = 0.9–315.5), respectively.
Mutations at DHPS codons were less frequent than DHFR mutations and were only found at codon 437. All mutations at codon 437 were observed in double-mutant DHFR samples (i.e., DHFR 108 and 51 mutants). The difference in marginal probability of DHFR 437 mutant parasites occurrence before and after therapy was not statistically different (P > 0.05). In addition, results of paired analysis for selection of DHPS mutant parasites before and after therapy were not significant.
Transmission potential (gametocytemia after treatment).
At enrollment, 13 (8.4%) of 155 individuals were carrying gametocytes. Gametocytemia peaked by day 7 after treatment when 112 (75.7%) of 148 individuals had detectable gametocytes, and the mean log10 gametocytemia was 2.56, which corresponded to 367 gametocytes/μL (n = 112). On days 14, 21, and 28, the corresponding statistics were 70.4% (100 of 142) and 282 gametocytes/μL, 58.8% (80 of 136) and 184 gametocytes/μL, and 40.2% (53 of 132) and 128 gametocytes/μL, respectively.
Infectivity.
At enrollment, most the MFAs showed no infection of mosquitoes because only 17 (11.0%) of 154 mosquito batches were positive for oocysts after mosquito feeding. Positivity of MFA peaked by day 7 after SP treatment when 73 (50.3%) of 145 batches showed positive mosquitoes, and decreased thereafter to 40.7% (57 of 140), 32.2% (29 of 90), and 14.1% (9 of 64) on days 14, 21, and 28, respectively. The average proportion of mosquitoes with oocysts per each batch was 2.9% at enrollment, peaked by day 7 (13.5%), and decreased to 9.7% (day 14), 4.1% (day 21), and 0.5% by the end of follow-up (day 28). Mean numbers of oocysts among positive assays were 4.8, 11.2, 6.8, 2.0, and 1.8 oocysts/mosquito by days 0, 7, 14, 21, and 28 after treatment, respectively. These results not only show that gametocytes after SP treatment are infectious but also suggest that infectivity reaches its peak 7 days after treatment with a higher probability of infected mosquitoes and a higher number of oocysts.
Mutations and infectivity.
Based on the observed selection of mutant parasites after treatment (i.e., by day 7 OR = 3.8 for selection of double-mutant 108 and 51 DHFR codons), and the concurrent higher probability of transmission in mosquitoes, we evaluated the relationship between occurrence of resistance-conferring mutations in parasites and infectivity to mosquitoes. Figure 1 shows the proportions of positive mosquitoes according to DHFR status and day of follow-up. Parasites found with point mutations at 108 and 51 DHFR codons showed higher proportions of infective mosquitoes before and after treatment. The OR of finding a mosquito infected reached statistical significance (P < 0.05) 7–14 days after treatment when point mutations at 108 and 51 were compared with no mutant infections (Table 5). During these days, DHFR double-mutant infections had 7–10 times the odds of infecting mosquitoes than infections with no mutations, and infectivity tended to decrease after that. In addition, among positive mosquitoes, the mean number of oocysts showed no differences (P > 0.10) between single- and double-mutant infections.
DISCUSSION
In this setting of high SP efficacy and low malaria transmission, our study suggests that parasites with DHFR mutations associated with SP resistance are selected by SP treatment, and demonstrates that after treatment gametocytes carrying these mutations are infective to mosquitoes. We previously reported that DHFR mutations associated with resistance in asexual parasites were associated with longer PCT and the presence of gametocytes after SP treatment.1 The present study demonstrates that gametocytes arising carrying resistance-conferring mutations are selected during the period after SP treatment. Selection of mutant sexual parasites peaks a week after treatment, when the individual probability of finding DHFR double-mutant gametocytes among infections that carried either one or no DHFR mutations increased nearly five-fold after adjusting by level of parasitemia (OR = 4.9).
We also measured parasite infectivity to Anopheles mosquitoes of post-treatment gametocytes with and without DHFR and DHPS mutations. Results of MFAs of An. albimanus mosquitoes with blood obtained after SP treatment demonstrated that gametocytes carrying DHFR and DHPS mutations are infective to mosquitoes. In addition, our data show that double-mutant infections are associated with a higher probability of finding infected mosquitoes. We demonstrated oocysts are more frequent in mutant infections, but certainly it would be of interest in another next study to look at transmission of sporozoites.
Consistent with our findings, a previous study conducted in The Gambia demonstrated that the presence of a multidrug-resistant haplotype was associated with significantly higher oocysts burdens after treatment with the combination of chloroquine and SP.13 Our study confirms that low-level drug resistance mutations have the potential to enhance transmission of P. falciparum and the spread of resistant parasites. Our findings highlight the need to anticipate drug resistance before it manifests itself as clinical treatment failure. Neither the DHFR triple-mutant nor the DHFP/DHPS quintuple-mutant parasites most strongly associated with clinical SP treatment failure14 have been detected on the Pacific coast of Colombia. Based on the rapid appearance of resistance after introduction of antifolates15,16 and the ability of a single point mutation to cause some degree of resistance to DHFR inhibitors,17 it was thought that antifolate resistance arises frequently through independent mutational events. However, the most highly antifolate-resistant forms of P. falciparum appear to have spread through other regions of South America in genetic sweeps rather than arising de novo on the background of single- and double-mutant DHFR and single-mutant DHPS that we see in our setting.18 Microsatellite analyses have shown that DHFR triple-mutant parasites from diverse geographic regions share common ancestry,19 which further supports the idea that the threat to SP efficacy in our region may be from the importation of highly resistant parasites from outside the area. To reconcile theory and data, it has been hypothesized that new, independently arising DHFR triple-resistance parasites are unlikely to survive or are actually killed by drug therapy.20
Whether SP resistance arises locally or is imported, anti-malarial drugs and drug combinations that eliminate both asexual and sexual parasites deserve priority because they will reduce transmission of drug-resistant parasites that are highly infectious to mosquitoes. High rates of SP resistance and highly mutated DHFR and DHPS have been found in the Amazonian eastern region of Colombia (F. Mendez, unpublished data), and the use of gametocytocidal treatments should be considered now as part of a strategy to preserve SP as an effective component of combination therapies. Combination therapies including drugs with both short- and long-acting parasite killing action would decrease PCT, reduce gametocytemia, and decrease the probability that mutant parasites will be selected and transmitted to mosquitoes. The evaluation of combination therapies would benefit from determining whether, after treatment, mutant parasites are present in sexual forms and if they are infective to mosquitoes.
Treatment response and total follow-up time after sulfadoxine-pyrimethamine treatment
| Days of follow-up | ||||||||
|---|---|---|---|---|---|---|---|---|
| Treatment response | Total | 1 | 2 | 3 | 7 | 14 | 21 | 28 |
| Treatment failure | 7 | 3 | 3 | 1 | 0 | 0 | 0 | 0 |
| Adequate clinical and parasitologic response | 148 | 0 | 0 | 0 | 6 | 6 | 4 | 132 |
| Total | 155 | 3 | 3 | 1 | 6 | 6 | 4 | 132 |
DHFR and DHPS mutations on enrollment when treatment was initiated (day 0) and during follow-up in 155 individuals with uncomplicated falciparum malaria*
| DHFR codons | DHPS codon | ||
|---|---|---|---|
| Days after treatment | 108 | 51 | 437 |
| * DHFR = dihydrofolate reductase; DHPS = dihydropteroate synthase. | |||
| Day 0 | |||
| Amplified | 153 | 153 | 153 |
| Mutant (%) | 132 (86.3) | 90 (58.8) | 16 (10.5) |
| Day 7 | |||
| Amplified | 88 | 100 | 82 |
| Mutant (%) | 79 (89.8) | 68 (68.0) | 12 (14.6) |
| Day 14 | |||
| Amplified | 75 | 79 | 70 |
| Mutant (%) | 69 (92.0) | 52 (65.8) | 7 (10.0) |
| Day 21 | |||
| Amplified | 47 | 48 | 46 |
| Mutant (%) | 44 (93.6) | 28 (58.3) | 3 (6.5) |
| Day 28 | |||
| Amplified | 37 | 36 | 36 |
| Mutant (%) | 37 (100.0) | 27 (75.0) | 3 (8.3) |
DHFR mutations on amplified samples (n) at 108 or 51 codons at enrollment and during follow-up after SP treatment*
| DHFR mutations | |||
|---|---|---|---|
| Days after treatment | No mutation | 108 mutant only | 108 and 51 mutants |
| * DHFR = dihydrofolate reductase; SP = sulfadoxine-pyrimethamine. Ranges are 95% exact confidence intervals. | |||
| † Nine samples found mutant for DHFR-51 were not amplified for DHFR-108, and were classified as double mutant (108 and 51 mutant). Four samples found no mutant for DHFR-51, were not amplified for DHFR-108, were classified as DHFR no mutant or 108 only mutant, and are not included in this table. One sample found no mutant for DHFR-108, was not amplified for DHFR-51, and was excluded. | |||
| Day 0 (n = 153) | 13.7% (n = 21) (8.7–20.2) | 27.5% (n = 42) (20.6–35.2) | 58.8% (n = 90) (50.6–60.7) |
| Day 7 (n = 96)† | 9.4% (n = 9) (4.4–17.1) | 19.8% (n = 19) (12.4–29.2) | 70.8% (n = 68) (60.7–79.7) |
| Day 14 (n = 79) | 7.6% (n = 6) (2.8–15.8) | 26.6% (n = 21) (17.3–37.7) | 65.8% (n = 52) (54.3–76.1) |
| Day 21 (n = 48) | 6.3% (n = 3) (1.3–17.2) | 35.4% (n = 17) (22.2–50.5) | 58.3% (n = 28) (43.2–72.4) |
| Day 28 (n = 36) | 0.0% (0.0–9.7) | 25.0% (n = 9) (12.1–42.2) | 75.0% (n = 27) 57.8–87.9) |
Paired analysis for DHFR mutations at 108 and 51 codons before (day 0) and after therapy (day 7)*
| Day 0 | |||
|---|---|---|---|
| 108 and 51 mutant | No mutant or 108 only | ||
| * DHFR = dihydrofolate reductase. | |||
| Day 7 | 108 and 51 mutants | 53 | 15 |
| No mutant or 108 only | 4 | 27 | |
Odds ratios of infected mosquitoes according to number of dihydrofolate reductase mutations in infection*
| Day | |||||
|---|---|---|---|---|---|
| 0 | 7 | 14 | 21 | 28 | |
| * CI = confidence interval. | |||||
| No mutations | 1 | 1 | 1 | 1 | |
| 108 only (95% CI) | 1.29 (0.64–2.58) | 4.09 (0.73–23.0) | 4.02 (0.55–29.53) | 2.02 (0.25–16.4) | 1 |
| 108 and 51 (95% CI) | 1.73 (0.92–3.24) | 10.23 (2.25–46.58) | 7.32 (1.12–47.71) | 4.70 (0.62–35.65) | 1.39 (0.72–2.66) |
Box plots of the proportion of infected mosquitoes with oocysts after feeding from the 153, 87, 71, 47 and 36 amplified samples (n) at days 0, 7, 14, 21 and 28 after treatment with sulfadoxine-pyrimethamine (SP) according to dihydrofolate reductase status of infection. Membrane feeding assays of 9, 8, and 1 samples corresponding to days 7, 14, and 21 were not available because of no surviving mosquitoes. Horizontal lines show medians. Boxes show 25th–75th percentiles (interquartile ranges [IQRs]). Error bars (whiskers) extend to upper adjacent values defined as the largest data point ≤ the 75th percentile + 1.5 IQR.
Citation: The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 77, 3; 10.4269/ajtmh.2007.77.438
Box plots of the proportion of infected mosquitoes with oocysts after feeding from the 153, 87, 71, 47 and 36 amplified samples (n) at days 0, 7, 14, 21 and 28 after treatment with sulfadoxine-pyrimethamine (SP) according to dihydrofolate reductase status of infection. Membrane feeding assays of 9, 8, and 1 samples corresponding to days 7, 14, and 21 were not available because of no surviving mosquitoes. Horizontal lines show medians. Boxes show 25th–75th percentiles (interquartile ranges [IQRs]). Error bars (whiskers) extend to upper adjacent values defined as the largest data point ≤ the 75th percentile + 1.5 IQR.
Citation: The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 77, 3; 10.4269/ajtmh.2007.77.438
Box plots of the proportion of infected mosquitoes with oocysts after feeding from the 153, 87, 71, 47 and 36 amplified samples (n) at days 0, 7, 14, 21 and 28 after treatment with sulfadoxine-pyrimethamine (SP) according to dihydrofolate reductase status of infection. Membrane feeding assays of 9, 8, and 1 samples corresponding to days 7, 14, and 21 were not available because of no surviving mosquitoes. Horizontal lines show medians. Boxes show 25th–75th percentiles (interquartile ranges [IQRs]). Error bars (whiskers) extend to upper adjacent values defined as the largest data point ≤ the 75th percentile + 1.5 IQR.
Citation: The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 77, 3; 10.4269/ajtmh.2007.77.438
Address correspondence to Fabián Méndez, Escuela de Salud Pública, Universidad del Valle, San Fernando, Calle 4B No. 36-140, Edificio 118, Cali, Colombia. E-mail: famendez@univalle.edu.co
Authors’ addresses: Fabián Méndez, Escuela de Salud Pública, Universidad del Valle, San Fernando, Calle 4B No. 36-140, Edificio 118, Cali, Colombia, Fax: 57-2-557 0425, E-mail: famendez@univalle.edu.co. Sócrates Herrera, Bermans Murrain, Andrés Gutiérrez, and Luz A. Moreno, Malaria Vaccine and Drug Testing Center, Carrera 35 No. 4A-53, A.A. 25574, Cali, Colombia, Telephone: 57-2-5583937, Fax: 57-2-5560141, E-mail: sherrera@inmuno.org. María Manzano, Universidad Nacional de Colombia, Sede Palmira, Colombia. Álvaro Muñoz, Department of Epidemiology. The Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, E-7648, Baltimore, MD 21205, E-mail: jvaldez@jhsph.edu. Christopher V. Plowe, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF 480, Baltimore, MD 21201, E-mail: cplowe@medicine.umaryland.edu.
Financial support: This study was supported in part by a grant AI055687-02 from the National Institutes of Health and the Universidad del Valle, Cali, Colombia.
REFERENCES
- 1↑
Méndez F, Muñoz A, Carrasquilla G, Jurado D, Arévalo-Herrera M, Cortese JF, Plowe CV, 2002. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol 156 :230–238.
- 2↑
Morrow RH, 2001. The epidemiology and control of malaria. Nelson KE, Williams CM, Graham NM, eds. Infectious Disease Epidemiology: Theory and Practice. Gaithersburg, MD: Aspen Publishers, 675–710.
- 3↑
Bishop A, 1954. The effect of sulphadiazine, proguanil and 2:4-diamino-6:7diisopropylpteridine upon gametocyte production in Plasmodium gallinaceum. Parasitology 45 :163–185.
- 4↑
Sucharit S, Surathin K, Tumrasvin W, Sucharit P, 1977. Chloroquine resistant Plasmodium falciparum in Thailand: susceptibility to Anopheles. J Med Assoc Thai 60 :648–654.
- 5↑
Sutherland C, Alloueche A, Curtis J, Drakeley CJ, Ord R, Durainsingh M, Greenwood BM, Pinder M, Warhust D, Targett GA, 2002. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 67 :578–585.
- 6↑
Espinal LS, 1968. Visión Ecológica del Departamento del Valle del Cauca. Valle, Colombia: Ed. Universidad del Valle. 1968.
- 7↑
Méndez F, Carrasquilla G, Muñoz A, 2000. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg 94 :367–371.
- 8↑
Olano V, Carrasquilla G, Mendez F, 1997. Transmission of urban malaria in Buenaventura, Colombia: entomological features. Pan Am J Public Health 1 :287–294.
- 9↑
Quiñónez ML, Suarez MF, Fleming GA, 1987. Distribución y bionomía de los anofelinos de la costa Pacífica colombiana. Colomb Med 18 :19–24.
- 10↑
World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. Geneva: World Health Organization. Technical Document 2003. WHO/HTM/RBM/2003.50.
- 11↑
Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of sulfadoxine-pyrimethamine use and resistance. J Infect Dis 176 :1590–1596.
- 12↑
Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arévalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91 :4.
- 13↑
Hallett RL, Dunyo S, Ord R, Jawara M, Pinder M, Randall A, Alloueche A, Walraven G, Targett G, Alexander N, Sutherland CJ, 2006. Chloroquine/sulphadoxine-pyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials 1 :e15.
- 14↑
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185 :380–388.
- 16↑
Clyde DF, Shute GT, 1957. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 51 :505–513.
- 17↑
Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 85 :9114–9118.
- 18↑
Cortese JF, Caraballo A, Contreras CE, Plowe CV, 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 :999–1006.
- 19↑
Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T, 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305 :1124.